Blueprint Medicines (BPMC) Tops Q3 EPS by 7c ; Offers Guidance

Blueprint Medicines (NASDAQ: BPMC) reported Q3 EPS of ($0.89), $0.07 better than the analyst estimate of ($0.96). Revenue for the quarter came in at $128.18 million versus the consensus estimate of $127.56 million.

GUIDANCE:

Blueprint Medicines sees FY2024 revenue of $475-480 million, versus the consensus of $497.3 million.

For earnings history and earnings-related data on Blueprint Medicines (BPMC) click here.

You May Also Be Interested In

• Cerebras Systems (CBRS) Misses Q1 EPS, Revenues Beat
• Alphabet added to Dow Jones Industrial Average, Verizon dropped
• Worthington Industries (WOR) Misses Q4 EPS by 9c